Literature DB >> 2757884

Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.

A Drøhse1, L Bathum, K Brøsen, L F Gram.   

Abstract

The oxidation of mephenytoin was polymorphic in 358 healthy Danish volunteers. The ratio between the chromatographic peak areas of (S)- and (R)-mephenytoin (S/R) in 12 h urine was less than or equal to 0.48 in 349 extensive metabolizers (EM) and greater than or equal to 1 in 9 (2.5%) poor metabolizers (PM). Concomitant intake of mephenytoin and sparteine and subsequent assay by gas chromatography had no influence on the test results (mephenytoin S/R ratio or sparteine metabolic ratio). Among ten parents and seven siblings to six unrelated PM of mephenytoin only one (1/17 = 5.9%) was a PM. The pedigrees were compatible with an autosomal recessive mode of inheritance.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2757884      PMCID: PMC1379929          DOI: 10.1111/j.1365-2125.1989.tb03426.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.

Authors:  K Nakamura; F Goto; W A Ray; C B McAllister; E Jacqz; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

2.  Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians.

Authors:  T Inaba; M Jurima; M Nakano; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1984-11       Impact factor: 6.875

3.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

4.  Mephenytoin hydroxylation deficiency: kinetics after repeated doses.

Authors:  A Küpfer; P Desmond; R Patwardhan; S Schenker; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1984-01       Impact factor: 6.875

5.  Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.

Authors:  A Küpfer; R Preisig
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  Genetic polymorphism of human cytochrome P-450 (S)-mephenytoin 4-hydroxylase. Studies with human autoantibodies suggest a functionally altered cytochrome P-450 isozyme as cause of the genetic deficiency.

Authors:  U T Meier; U A Meyer
Journal:  Biochemistry       Date:  1987-12-15       Impact factor: 3.162

7.  Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians.

Authors:  M Jurima; T Inaba; D Kadar; W Kalow
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

Review 8.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

9.  Sparteine metabolism in Canadian Caucasians.

Authors:  A Vinks; T Inaba; S V Otton; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1982-01       Impact factor: 6.875

10.  Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.

Authors:  P J Wedlund; W S Aslanian; C B McAllister; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1984-12       Impact factor: 6.875

View more
  14 in total

1.  Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.

Authors:  L Bathum; E Skjelbo; T K Mutabingwa; H Madsen; M Hørder; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

2.  Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol.

Authors:  T Andersson; P Lundborg; C G Regårdh
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

4.  Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies.

Authors:  Y Zhang; R A Blouin; P J McNamara; J Steinmetz; P J Wedlund
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

5.  Frequency of S-mephenytoin hydroxylation deficiency in 373 Spanish subjects compared to other Caucasian populations.

Authors:  J Reviriego; L Bertilsson; J A Carrillo; A Llerena; M J Valdivielso; J Benítez
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.

Authors:  H Madsen; K K Nielsen; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

Review 7.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 8.  Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19.

Authors:  D A Flockhart
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

9.  Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark.

Authors:  K Brøsen; E Skjelbo; H Flachs
Journal:  Br J Clin Pharmacol       Date:  1993-08       Impact factor: 4.335

10.  S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphisms in a Turkish population.

Authors:  N E Basci; K Brosen; A Bozkurt; A Isimer; A Sayal; S O Kayaalp
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.